Concise review: Immune recognition of induced pluripotent stem cells

Stem Cells

Volumn 30, Issue 5, 2012, Pages 797-803

  Boyd, Ashleigh S ^a   Rodrigues, Neil P ^a   Lui, Kathy O ^b   Fu, Xuemei ^c,d   Xu, Yang ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c SECTION OF MOLECULAR BIOLOGY   (United States)

^d CHENGDU WOMEN S AND CHILDREN S CENTRAL HOSPITAL   (China)

Author keywords

Cell replacement therapy; Embryonic stem cells; Immunogenicity; Induced pluripotent stem cells; Regenerative medicine; Rejection; Stem cells; Tolerance; Transplantation

Indexed keywords

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; EMBRYONIC STEM CELL; EPIGENETICS; GENETIC DISORDER; GENETIC STABILITY; GRAFT SURVIVAL; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; NONHUMAN; PLURIPOTENT STEM CELL; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; GRAFT REJECTION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 84860508896     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1066     Document Type: Review

References (54)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676. (Pubitemid 44233629)
2. Hanna J, Wernig M, Markoulaki S et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-1923.
3. Zhao T, Zhang Z-N, Rong Z et al. Immunogenicity of induced pluripotent stem cells. Nature 2011;474:212-215.
4. Bar-Nur O, Russ Holger A, Efrat S et al. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem cell 2011;9:17-23.
5. Polo JM, Liu S, Figueroa ME et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010;28:848-855.
6. Swijnenburg RJ, Tanaka M, Vogel H et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005;112: I166-I172. (Pubitemid 41266669)
7. Boyd AS, Wood KJ. Variation in MHC expression between undifferentiated mouse ES cells and ES cell-derived insulin-producing cell clusters. Transplantation 2009;87:1300-1304.
8. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872. (Pubitemid 350138099)
9. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318: 1917-1920.
10. Park IH, Zhao R, West JA et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008;451: 141-146.
11. Doi A, Park IH, Wen B et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009;41:1350-1353.
12. Deng J, Shoemaker R, Xie B et al. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol 2009;27:353-360.
13. Lister R, Pelizzola M, Kida YS et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471:68-73.
14. Boyd AS, Fairchild PJ. Approaches for immunological tolerance induction to stem cell-derived cell replacement therapies. Expert Rev Clin Immunol 2010;6:435-448.
15. Panopoulos Athanasia D, Ruiz S, Belmonte Juan Carlos I. iPSCs: Induced back to controversy. Cell Stem Cell 2011;8:347-348.
16. Gore A, Li Z, Fung HL et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011;471:63-67.
17. Laurent LC, Ulitsky I, Slavin I et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011;8:106-118.
18. Hussein SM, Batada NN, Vuoristo S et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011;471: 58-62.
19. Utikal J, Polo JM, Stadtfeld M et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009; 460:1145-1148.
20. Marion RM, Strati K, Li H et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009;460:1149-1153.
21. Li H, Collado M, Villasante A et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009;460:1136-1139.
22. Kawamura T, Suzuki J, Wang YV et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009;460: 1140-1144.
23. Hong H, Takahashi K, Ichisaka T et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009;460: 1132-1135.
24. Zhao T, Xu Y. p53 and stem cells: New developments and new concerns. Trends Cell Biol 2010;20:170-175.
25. Drukker M, Katz G, Urbach A et al. Characterization of the expression of MHC proteins in human embryonic stem cells. PNAS 2002; 99:9864-9869. (Pubitemid 34831138)
26. Robertson NJ, Brook FA, Gardner RL et al. Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci USA 2007; 104:20920-20925.
27. Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009;460:53-59.
28. Dhodapkar KM, Feldman D, Matthews P et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci 2010;107: 8718-8723.
29. Tang C, Lee AS, Volkmer JP et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratomaforming cells. Nat Biotechnol 2011;29:829-834.
30. Daley GQ, Scadden DT. Prospects for stem cell-based therapy. Cell 2008;132:544-548. (Pubitemid 351253699)
31. Boyd AS, Wood KJ. Characteristics of the early immune response following transplantation of mouse ES cell derived insulin-producing cell clusters. PLoS One 2010;5:e10965.
32. Wu DC, Boyd AS, Wood KJ. Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells 2008;26:1939-1950.
33. Dressel R, Nolte J, Elsner L et al. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. The FASEB J 2010;24:2164-2177.
34. Kabelitz D, Medzhitov R. Innate immunity - Cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr Opin Immunol 2007;19:1-3. (Pubitemid 46091738)
35. Li L, Baroja ML, Majumdar A et al. Human embryonic stem cells possess immune-privileged properties. Stem Cells 2004;22: 448-456. (Pubitemid 39014562)
36. Drukker M, Katchman H, Katz G et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 2006;24:221-229. (Pubitemid 44464789)
37. Swijnenburg RJ, Schrepfer S, Govaert JA et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci USA 2008;105:12991-12996.
38. Lui KO, Boyd AS, Cobbold SP et al. A Role for Regulatory T Cells in Acceptance of ESC-Derived Tissues Transplanted Across an Major Histocompatibility Complex Barrier. Vol 28. Wiley Subscription Services, Inc., A Wiley Company: Stem Cells, 2010:1905-1914.
39. Goldstein DR. T cell costimulation blockade and organ transplantation: A change of philosophy for transplant immunologists? J Immunol 2011;186:2691-2692.
40. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438. (Pubitemid 26162734)
41. Grinnemo K-H, Genead R, Kumagai-Braesch M et al. Costimulation blockade induces tolerance to HESC transplanted to the testis and induces regulatory T-cells to HESC transplanted into the heart. Stem Cells 2008;26:1850-1857.
42. Pearl Jeremy I, Lee Andrew S, Leveson-Gower Dennis B et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011;8:309-317.
43. Larsen CP, Elwood ET, Alexander DZ et al. Pillars article: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996. 381: 434-438. 1996.
44. J Immunol 2011; 186:2693-2697.
45. Legrand N, Dontje W, van Lent AU et al. Human thymus regeneration and T cell reconstitution. Semin Immunol 2007;19:280-288. (Pubitemid 350181527)
46. Seach N, Layton D, Lim J et al. Thymic generation and regeneration: A new paradigm for establishing clinical tolerance of stem cell-based therapies. Curr Opin Biotechnol 2007;18:441-447. (Pubitemid 350119857)
47. Gibbons C, Sykes M. Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism. Immunol Rev 2008;223:334-360. (Pubitemid 351986181)
48. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007;7:585-598. (Pubitemid 47123554)
49. Andersson J, Tran DQ, Pesu M et al. CD4+FoxP3+ regulatory T cells confer infectious tolerance in a TGF-{beta}-dependent manner. J Exp Med 2008;205:1975-1981.
50. Shevach EM, Davidson TS, Huter EN et al. Role of TGF-beta in the induction of Foxp3 expression and T regulatory cell function. J Clin Immunol 2008;28:640-646.
51. Schmitt TM, de Pooter RF, Gronski MA et al. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol 2004;5:410-417. (Pubitemid 38500090)
52. Senju S, Hirata S, Matsuyoshi H et al. Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells. Blood 2003;101:3501-3508. (Pubitemid 36857934)
53. Senju S, Haruta M, Matsumura K et al. Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther 2011;18:874-883.
54. Zhou Z, French DL, Ma G et al. Development and function of myeloid- derived suppressor cells generated from mouse embryonic and hematopoietic. Stem Cells 2010;28:620-632.